Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ecke

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
International Journal of Molecular Sciences|October 14, 2020
Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant ChemotherapyThorsten H Ecke, Adisch Kiani, Thorsten Schlomm, et al.
BJU International|June 26, 2024
Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trialIngmar Wolff, Anton P Kravchuk, Ralph M Wirtz, et al.
International Journal of Molecular Sciences|July 27, 2022
Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene AssessmentThorsten H Ecke, Paula Carolin Voß, Thorsten Schlomm, et al.
Clinical Chemistry|March 9, 2010
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancersCatharine M Sturgeon, Michael J Duffy, Barry R Hofmann, et al.
Urologic Oncology|March 3, 2018
Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer networkTahlita C M Zuiverloon, Kim E M van Kessel, Trinity J Bivalacqua, et al.
Urology|December 3, 2024
Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to CytologyThorsten H Ecke, Christina J Meisl, Thorsten Schlomm, et al.
Urologic Oncology|July 5, 2023
BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter studyThorsten H Ecke, Christina J Meisl, Thorsten Schlomm, et al.
BJU International|December 20, 2021
Nomograms including the UBC<sup>®</sup> Rapid test to detect primary bladder cancer based on a multicentre datasetChristina J Meisl, Pierre I Karakiewicz, Roland Einarsson, et al.
European Urology|February 21, 2024
Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial CancerNicolaus F Debatin, Elena Bady, Tim Mandelkow, et al.
Frontiers in Bioscience (Elite Edition)|June 2, 2012
Bladder cancer documentation of causes: multilingual questionnaire, 'bladder cancer doc'Klaus Golka, Yael Abreu-Villaca, Rowshanak Anbari Attar, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
International Journal of Molecular Sciences|October 14, 2020
Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of <i>KRT5</i>, <i>KRT20</i>, and <i>ERBB2</i> in Muscle-Invasive Bladder Cancer Treated by Adjuvant ChemotherapyThorsten H Ecke, Adisch Kiani, Thorsten Schlomm, et al.
BJU International|June 26, 2024
Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trialIngmar Wolff, Anton P Kravchuk, Ralph M Wirtz, et al.
International Journal of Molecular Sciences|July 27, 2022
Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene AssessmentThorsten H Ecke, Paula Carolin Voß, Thorsten Schlomm, et al.
Clinical Chemistry|March 9, 2010
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancersCatharine M Sturgeon, Michael J Duffy, Barry R Hofmann, et al.
Urologic Oncology|March 3, 2018
Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer networkTahlita C M Zuiverloon, Kim E M van Kessel, Trinity J Bivalacqua, et al.
Urology|December 3, 2024
Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to CytologyThorsten H Ecke, Christina J Meisl, Thorsten Schlomm, et al.
Urologic Oncology|July 5, 2023
BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter studyThorsten H Ecke, Christina J Meisl, Thorsten Schlomm, et al.
BJU International|December 20, 2021
Nomograms including the UBC<sup>®</sup> Rapid test to detect primary bladder cancer based on a multicentre datasetChristina J Meisl, Pierre I Karakiewicz, Roland Einarsson, et al.
European Urology|February 21, 2024
Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial CancerNicolaus F Debatin, Elena Bady, Tim Mandelkow, et al.
Frontiers in Bioscience (Elite Edition)|June 2, 2012
Bladder cancer documentation of causes: multilingual questionnaire, 'bladder cancer doc'Klaus Golka, Yael Abreu-Villaca, Rowshanak Anbari Attar, et al.
Pageof 14